B6.129P2/Ola-Nr3c1tm2.1Gsc/Cnrm

Status

Available to order

EMMA IDEM:00608
Citation informationRRID:IMSR_EM:00608 

Research Resource Identifiers (RRID) are persistent unique ID numbers assigned to help researchers cite key resources (e.g. antibodies, model organisms and software projects) in the biomedical literature to improve transparency and reproducibility in research. See https://www.rrids.org/ for more information.

 
International strain nameB6.129P2/Ola-Nr3c1tm2.1Gsc/Cnrm
Alternative nameGRnull
Strain typeTargeted Mutant Strains : Knock-out
Allele/Transgene symbolNr3c1tm2.1Gsc
Gene/Transgene symbolNr3c1

Information from provider

ProviderGünther Schütz
Provider affiliationMolecular Biology of the Cell I, German Cancer Research Center
Genetic informationRemoval of the floxed first Zn-finger domain sequence (exon 3, flanked by loxP sites) by crossing with a cre recombinase-deleter mouse.
Phenotypic informationFailure of lung inflation after birth. Hypothalamic-pituitary-adrenal (HPA) axis alteration. Skin defects.
References
  • Analysis of mice carrying targeted mutations of the glucocorticoid receptor gene argues against an essential role of glucocorticoid signalling for generating adrenal chromaffin cells.;Finotto S, Krieglstein K, Schober A, Deimling F, Lindner K, Brühl B, Beier K, Metz J, Garcia-Arraras J E, Roig-Lopez J L, Monaghan P, Schmid W, Cole T J, Kellendonk C, Tronche F, Schütz G, Unsicker K, ;1999;Development (Cambridge, England);126;2935-44; 10357937

Information from EMMA

Archiving centreCNR, Consiglio Nazionale delle Ricerche, Monterotondo, Italy

Disease and phenotype information

Orphanet associated rare diseases, based on orthologous gene matching

MGI phenotypes (allele matching)
  • increased susceptibility to experimental autoimmune encephalomyelitis / MGI
  • abnormal blood-brain barrier function / MGI
  • decreased T cell apoptosis / MGI
  • absent circulating adrenaline / MGI
  • decreased circulating noradrenaline level / MGI
  • abnormal adrenal chromaffin cell morphology / MGI
  • decreased erythroid progenitor cell number / MGI
  • neonatal lethality, complete penetrance / MGI
  • abnormal osteoblast physiology / MGI
  • skeleton phenotype / MGI
  • abnormal osteoblast differentiation / MGI
MGI phenotypes (gene matching)
  • abnormal liver physiology / MGI
  • abnormal adrenal gland morphology / MGI
  • enlarged adrenal glands / MGI
  • absent adrenal medulla / MGI
  • absent adrenergic chromaffin cells / MGI
  • enlarged adrenocortical cells / MGI
  • abnormal lung morphology / MGI
  • abnormal lung development / MGI
  • atelectasis / MGI
  • thick pulmonary interalveolar septum / MGI
  • cyanosis / MGI
  • absent circulating adrenaline / MGI
  • increased circulating corticosterone level / MGI
  • increased circulating adrenocorticotropin level / MGI
  • respiratory failure / MGI
  • respiratory distress / MGI
  • no abnormal phenotype detected / MGI
  • abnormal pulmonary alveolus morphology / MGI
  • abnormal pulmonary alveolus epithelial cell morphology / MGI
  • abnormal alveolocapillary membrane morphology / MGI
  • decreased circulating adrenocorticotropin level / MGI
  • decreased circulating corticosterone level / MGI
  • increased circulating aldosterone level / MGI
  • small adrenal glands / MGI
  • decreased circulating testosterone level / MGI
  • abnormal respiratory system development / MGI
  • decreased macrophage cell number / MGI
  • pulmonary hyperplasia / MGI
  • abnormal surfactant secretion / MGI
  • increased susceptibility to experimental autoimmune encephalomyelitis / MGI
  • increased mean systemic arterial blood pressure / MGI
  • abnormal osteoblast physiology / MGI
  • decreased B cell number / MGI
  • abnormal blood-brain barrier function / MGI
  • abnormal circulating corticosterone level / MGI
  • renal/urinary system phenotype / MGI
  • adipose tissue phenotype / MGI
  • homeostasis/metabolism phenotype / MGI
  • growth/size/body region phenotype / MGI
  • skeleton phenotype / MGI
  • increased renin activity / MGI
  • increased lung weight / MGI
  • decreased circulating noradrenaline level / MGI
  • impaired lung alveolus development / MGI
  • increased systemic arterial systolic blood pressure / MGI
  • increased circulating angiotensinogen level / MGI
  • decreased T cell apoptosis / MGI
  • decreased CD4-positive, alpha beta T cell number / MGI
  • decreased CD8-positive, alpha-beta T cell number / MGI
  • abnormal adrenal cortex morphology / MGI
  • enlarged adrenocortical cell nuclei / MGI
  • abnormal adrenal gland zona glomerulosa morphology / MGI
  • abnormal adrenal gland zona fasciculata morphology / MGI
  • abnormal adrenal gland zona reticularis morphology / MGI
  • thin adrenal cortex / MGI
  • abnormal osteoblast differentiation / MGI
  • abnormal adrenal chromaffin cell morphology / MGI
  • decreased survivor rate / MGI
  • abnormal physiological response to xenobiotic / MGI
  • decreased erythroid progenitor cell number / MGI
  • abnormal thymocyte apoptosis / MGI
  • increased liver triglyceride level / MGI
  • increased type II pneumocyte number / MGI
  • decreased type I pneumocyte number / MGI
  • abnormal branching involved in terminal bronchiole morphogenesis / MGI
  • postnatal lethality, complete penetrance / MGI
  • neonatal lethality, complete penetrance / MGI
  • neonatal lethality, incomplete penetrance / MGI
  • perinatal lethality, complete penetrance / MGI
  • perinatal lethality, incomplete penetrance / MGI
  • decreased noradrenaline level / MGI
  • decreased adrenaline level / MGI

Literature references

  • Analysis of mice carrying targeted mutations of the glucocorticoid receptor gene argues against an essential role of glucocorticoid signalling for generating adrenal chromaffin cells.;Finotto S, Krieglstein K, Schober A, Deimling F, Lindner K, Brühl B, Beier K, Metz J, Garcia-Arraras J E, Roig-Lopez J L, Monaghan P, Schmid W, Cole T J, Kellendonk C, Tronche F, Schütz G, Unsicker K, ;1999;Development (Cambridge, England);126;2935-44; 10357937
  • The balance between gluco- and mineralo-corticoid action critically determines inflammatory adipocyte responses.;Hoppmann J, Perwitz N, Meier B, Fasshauer M, Hadaschik D, Lehnert H, Klein J, ;2010;The Journal of endocrinology;204;153-64; 19939912

Information on how we integrate external resources can be found here

Order

Availabilities

Requesting frozen sperm or embryos is generally advisable wherever possible, in order to minimise the shipment of live mice.

  • Frozen embryos. Delivered in 4 weeks (after paperwork in place). €1740*
  • Rederivation of mice from frozen stock, delivery time available upon request . €3880*

Due to the dynamic nature of our processes strain availability may change at short notice. The local repository manager will advise you in these circumstances.

* In addition users have to cover all the shipping costs (including the cost for returning dry-shippers, where applicable).

More details on pricing and delivery times

Practical information

Genotyping protocol

Example health report
(Current health report will be provided later)

Material Transfer Agreement (MTA)
Distribution of this strain is subject to a provider MTA. Both signing of the MTA and submission of the online EMMA Mutant Request Form are required before material can be shipped.

EMMA conditions
Legally binding conditions for the transfer

Other EMMA strains

Not found what you were looking for? Search here for other strains available from EMMA.


Search
INFRAFRONTIER® and European Mouse Mutant Archive - EMMA® are registered trademarks at the European Union Intellectual Property Office (EUIPO).